Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CPB1 | P15086 | 4/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 2/20 | 0.35 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALPG | P10696 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4673968 | 0.81 | ALDH1A1 (0.40) | CPB2ALDH1A1CPB1AKR1B1CSNK2A2 | |
| SCHEMBL239541 | 0.79 | CYP2C9 (0.49) | CPB2ALDH1A1CPB1AKR1B1 | |
| SCHEMBL1911274 | 0.78 | CPB2 (0.46) | CPB2ALDH1A1CPB1ALOX15LMNA | |
| Hydrochloric Acid SCHEMBL9803746 | 0.77 | TDP1 (0.50) | CPB2ALDH1A1CPB1AKR1B1 | |
| SCHEMBL4832580 | 0.77 | ALPL (0.54) | ALDH1A1AKR1B1ALPLPLAAALPG | |
| SCHEMBL19602329 | 0.76 | TAAR1 (0.41) | CPB2ALDH1A1CPB1LMNA | |
| SCHEMBL3955613 | 0.76 | — | — | |
| SCHEMBL14523660 | 0.75 | CPB2 (0.45) | CPB2CPB1 | |
| SCHEMBL365026 | 0.75 | CPB2 (0.45) | CPB2CPB1 | |
| SCHEMBL1441194 | 0.74 | CPB2 (0.50) | CPB2ALDH1A1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225252-B1 | C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES | NOVARTIS AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2225252-B1 | C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES | NOVARTIS AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| US-20110224173-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2011-09-15 | — | — | US | disclosed |
| US-20110224173-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2011-09-15 | — | — | US | disclosed |
| US-20110224173-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2011-09-15 | — | — | US | disclosed |
| US-7977323-B2 | C2-C5-alkyl-imidazole-bisphosphonates | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-7977323-B2 | C2-C5-alkyl-imidazole-bisphosphonates | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-7977323-B2 | C2-C5-alkyl-imidazole-bisphosphonates | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| CN-102046152-A | Pharmaceutical compositions containing bisphosphonates | NOVARTIS AG | 2011-05-04 | — | — | CN | disclosed |
| US-20110034418-A1 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2011-02-10 | — | — | US | disclosed |
| US-20110034418-A1 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2011-02-10 | — | — | US | disclosed |
| US-20110034418-A1 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2011-02-10 | — | — | US | disclosed |
| EP-2273980-A2 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| CN-101835787-A | C2-C5-alkyl-imidazole-bisphosphonates | NOVARTIS AG | 2010-09-15 | — | — | CN | disclosed |
| WO-2009121935-A2 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009121935-A2 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | NOVARTIS AG (CH) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009068567-A1 | C2-C5-ALKYL-IMIDAZOLE-BISPHOSPHONATES | NOVARTIS AG (CH) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143337-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2009-06-04 | — | — | US | disclosed |
| US-20090143337-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2009-06-04 | — | — | US | disclosed |
| US-20090143337-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | NOVARTIS AG (CH) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224173-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | INPP5B, PPIP5K2, INPPL1 | CPB2 1983/4885ALDH1A1 4630/4885CPB1 1707/4885 |
| US-20110034418-A1 | PHARMACEUTICAL COMPOSITION WITH BISPHOSPHONATE | SOST, SLC20A1, SLC34A1 | CPB2 4200/4885ALDH1A1 3443/4885CPB1 3659/4885 |
| US-20090143337-A1 | C2-C5-Alkyl-Imidazole-Bisphosphonates | PPIP5K2, INPP5B, INPPL1 | CPB2 1761/4885ALDH1A1 4597/4885CPB1 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.